AbbVie Stock Surges 79 on Volume Rankings as FDA Filing Drives Investor Optimism

On July 29, 2025, AbbVie (ABBV) saw a 1.43% rise in its stock price, with a trading volume of $1.28 billion—a 79.66% surge from the previous day—ranking it 68th in market activity. The biopharmaceutical giant submitted a supplemental New Drug Application (sNDA) to the FDA for a VENCLEXTA® and acalabrutinib combination regimen in treating chronic lymphocytic leukemia (CLL), following positive Phase 3 trial results. This regulatory filing aligns with AbbVie’s strategy to expand its oncology portfolio, potentially boosting investor confidence.

Analysts have maintained a cautiously optimistic outlook. Guggenheim reiterated a “Buy” rating with a $216 price target, while JPMorgan reaffirmed an Overweight rating and $200 target, citing sustained growth in Skyrizi and Rinvoq sales. Institutional investors showed mixed activity: First National Trust Co reduced its position by 9.8%, whereas hedge funds like Crestline Management LP and Narus Financial Partners LLC increased stakes, reflecting divergent views on near-term prospects.

The company’s upcoming Q2 earnings report will be critical, with expectations of revenue growth driven by key therapies. AbbVie’s 8.4% year-on-year revenue increase in Q1, exceeding estimates by 3.3%, highlights its consistent performance. Additionally, the firm’s 3.42% dividend yield, with a $1.64 per share payout scheduled for August 15, remains a draw for income-focused investors.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a 166.71% return from 2022 to the present, significantly outperforming the benchmark return of 29.18%. The strategy's excess return was 137.53%, and it achieved a CAGR of 31.89%. With a maximum drawdown of 0.00% and a Sharpe ratio of 1.14, the strategy demonstrated strong risk-adjusted performance and capital preservation.